The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L02 | Endocrine therapy | |
| 3 | L02A | Hormones and related agents | |
| 4 | L02AE | Gonadotropin releasing hormone analogues | |
| 5 | L02AE05 |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| PAREN - Parenteral | 137 mg |
| Active Ingredient | Description | |
|---|---|---|
| Histrelin |
Histrelin is a gonadotropin releasing hormone (GnRH) agonist and an inhibitor of gonadotropin secretion when given continuously. It is indicated for the treatment of children with central precocious puberty (CPP). However, continuous administration of histrelin acetate causes a reversible down-regulation of the GnRH receptors in the pituitary gland and desensitization of the pituitary gonadotropes. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| VANTAS Implant | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
